妊娠合并甲状腺功能减退症激素替代治疗后的妊娠结局分析被引量：1

下载PDF

导出

摘要目的探究妊娠合并甲状腺功能减退症激素替代治疗后的妊娠结局。方法选择2014年8月~2016年8月收治的甲状腺功能减退孕妇40例为A组,亚临床甲状腺功能减退孕妇40例为B组,及同期收治的甲状腺功能正常孕妇40例为C组。A、B两组给予激素替代治疗,对比三组妊娠结局。结果 A组妊娠期高血压发病率为17.5%,胎膜早破发病率为30.0%,均显著高于C组,差异有统计学意义（P〈0.05）。三组妊娠期糖尿病、羊水过少、胎心率不可靠、妊娠并发症发生率对比,差异无统计学意义（P〉0.05）;三组新生儿早产、出生孕期、出生体重对比,差异无统计学意义（P〉0.05）。结论妊娠合并甲状腺功能减退症采用激素替代治疗,整体妊娠结局与正常孕妇相似,可控制妊娠结局在正常范围内。

作者夏奇彩

机构地区河南省郑州市黄河中心医院

出处《实用妇科内分泌电子杂志》 2016年第20期117-117,119,共2页 Electronic Journal of Practical Gynecological Endocrinology

关键词妊娠合并甲状腺功能减退症激素的替代治疗妊娠结局

分类号 R714.256 [医药卫生—妇产科学]

引文网络
相关文献

参考文献3

1王少为,李旻,褚德发,梁琳,赵晓东,张俊荣.妊娠早期合并临床或亚临床甲状腺功能减退症和甲状腺自身抗体阳性与早产发生风险的荟萃分析[J].中华妇产科杂志,2014,49(11):816-822. 被引量：46
2孔丽丽,周金华,黄沁.妊娠合并亚临床甲状腺功能减退症的早期治疗对妊娠结局的影响[J].实用妇产科杂志,2014,30(12):937-939. 被引量：75
3孙翀.妊娠合并甲状腺功能减退症和亚临床甲状腺功能减退症对妊娠结局的影响[J].中国妇幼保健,2013,28(35):5810-5812. 被引量：71

二级参考文献46

1Iams JD.Clinical practice.Prevention of preterm parturition[J].N Engl J Med,2014,370:254-261.
2Mannisto T,Mendola P,Grewal J,et al.Thyroid diseases and adverse pregnancy outcomes in a contemporary US cohort[J].J Clin Endocrinol Metab,2013,98:2725-2733.
3Haddow JE,Palomaki GE,Allan WC,et al.Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child[J].N Engl J Med,1999,341:549-555.
4Shan ZY,Chen YY,Teng WP,et al.A study for maternal thyroid hormone deficiency during the first half of pregnancy in China[J].Eur J Clin Invest,2009,39:37-42.
5Brent GA.The debate over thyroid-function screening in pregnancy[J].N Engl J Med,2012,366:562-563.
6Abalovich M,Amino N,Barbour LA,et al.Management of thyroid dysfunction during pregnancy and postpartum:an Endocrine Society Clinical Practice Guideline[J].J ClinEndocrinol Metab,2007,92:S1-47.
7Negro R,Schwartz A,Gismondi R,et al.Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes[J].J Clin Endocrinol Metab,2011,96:E920-924.
8Pradhan M,Anand B,Singh N,et al.Thyroid peroxidase antibody in hypothyroidism:it's effect on pregnancy[J].J Matern Fetal Neonatal Med,2013,26:581-583.
9Well GA,Shea B,O' Connell D,et al.The Newcastle-Ottawa Scale (NOS)for assessing the quality of nonrandomised studies in meta analyses[DB/OL].[2014-01-31]http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
10Korevaar TI,Schalekamp-Timmermans S,de Rijke YB,et al.Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery:the generation R study[J].J Clin Endocrinol Metab,2013,98:4382-4390.